Artificial surfactant therapy in hyaline-membrane disease.
about
Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infantsComparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infantsAnimal derived surfactant extract for treatment of respiratory distress syndromeHydrophobic surfactant-associated polypeptides: SP-C is a lipopeptide with two palmitoylated cysteine residues, whereas SP-B lacks covalently linked fatty acyl groupsUse of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activitycDNA and deduced amino acid sequence of human pulmonary surfactant-associated proteolipid SPL(Phe)The use of surfactant in the neonatal period- the known aspects, those still under research and those which need to be investigated furtherMy tribute to Mary ellen averyHydrophobic 3.7 kDa surfactant polypeptide: structural characterization of the human and bovine formsSP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lungComparative study of clinical pulmonary surfactants using atomic force microscopyInterfacial sensing by alveolar type II cells: a new concept in lung physiology?Micelles of pulmonary surfactant in human amniotic fluid at term.Introducing new cost effective treatments into the NHS. Surfactant treatment for premature babies: who cares enough to pay?Pulmonary surfactant therapy.Prognostic value of the immediate response to surfactantChronic lung disease in the preterm infant. Lessons learned from animal modelsThe molecular era of surfactant biology.Early prophylactic versus late selective use of surfactant for respiratory distress syndrome in very preterm infants: a collaborative study of 53 multi-center trials in Korea.Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties.Comparison of poractant alfa and lyophilized lucinactant in a preterm lamb model of acute respiratory distress.Pulmonary surfactant and its apoproteins.Vitamin K-dependent carboxylation of pulmonary surfactant-associated proteins.The evolution of neonatology.Current perspectives in assessment of fetal pulmonary surfactant status with amniotic fluid.Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study.Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome.Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review.Environmental Pollutant Ozone Causes Damage to Lung Surfactant Protein B (SP-B).Surfactant-anti-surfactant immune complexes in infants with respiratory distress syndrome.Changes in respiratory elastance after deep inspirations reflect surface film functionality in mice with acute lung injuryThe role of surfactant in respiratory distress syndromeSurfactant metabolism in the neonate.History of surfactant up to 1980.History of surfactant from 1980.New synthetic surfactants: the next generation?Surfactant administration via a thin endotracheal catheter during spontaneous breathing in preterm infants.Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.Short- and Long-Term Outcomes for Extremely Preterm Infants.Paediatrics--Part I.
P2860
Q24187014-9C51855B-69B3-4D7A-805B-C28743124039Q24197942-43C45897-1550-4130-9190-4EFFA3AE8629Q24241741-11D92B1D-6ABC-466B-82D3-FC198568E5DEQ24558711-F18D25DD-ECFE-4F06-9E65-AF56029423A8Q24561593-43975522-AD0C-46CD-9874-9811CAAD7F65Q24606767-8C2EA21D-5E70-4250-A4E5-BBF8FA905E80Q26864160-0DC384D6-FE4F-4074-BBFF-BF0ED502FCB2Q26999996-54AFB598-1BC2-458E-B7E2-76EE7DE7C444Q28297099-052A7A96-8DE1-48AD-9D21-CA9AD7801308Q28727044-96CBFB97-36AE-4F6C-A802-BD73E72393E8Q28833705-38181F9F-B924-497C-8EEA-990744A219D1Q30501348-90B7C989-EAC9-49AC-A6E5-A1DFC95FCAD2Q33251612-F9C8B2B5-C8D2-43FD-9675-054406DD5D5CQ33553638-672264F3-975E-4F62-A5BF-D310FE7964BAQ33608041-FFFDF7B5-AD0E-43A3-9CA8-A161DD6D88A2Q33706583-C8F963BD-B5D0-46B0-A065-F0D58EE74E10Q33756577-3918A03B-D903-463A-BE9F-918BDBF731EBQ33942221-CC343AF0-D5D7-4EE9-A6F0-51D30C44551FQ34030003-A15B32B4-686E-4102-8F82-350F37B98436Q34152702-C2191F93-2DD1-4E1D-BB0B-8604183E5AFCQ34215878-FE91CCDF-22E9-4565-885B-E20B8C375C0BQ34254562-4FA52D56-B016-4CDA-943C-318EE7A5C504Q34340795-6A8D585A-7385-407B-A412-6F08A863E25FQ34395577-BC88844F-AB0D-4731-86E0-B8B9847A3B4BQ34508715-12B8BE42-72C0-4F68-8C9A-EEE1853F7CF9Q35086075-6A4FC57A-5FEA-401C-8D15-B0447203CDE2Q35605423-2168AA61-640D-4E76-8C44-766F78E30988Q35627775-5DD2E426-205F-44A9-8615-43676A342B5FQ35744814-9D206769-F996-42A0-84DA-AA60CA5B111DQ35835631-6594554D-A122-4147-B7B0-3D6903C47006Q35921743-A6534355-590B-48F5-AEB0-58122C41C30BQ36131235-DF5FF553-D63E-4C76-960B-CC9F82D2789AQ36178009-B5F26513-AD0C-4D82-AAE9-ACCE08309B20Q36178013-3C1457E4-7BFF-4C71-919B-9350F7CA8A6EQ36178017-F4729D98-61C9-464F-9F60-052C135C0B8BQ36178027-456E900A-720E-4C90-AC53-08317E858475Q36268039-8D05AF05-85A3-4926-8B5A-FC843891F9CBQ36580296-36D620E8-BA9B-47F7-8472-FE1D314DE581Q36599103-65B932BA-9937-4A5C-9368-AB1FBF33141FQ36683473-585F5680-99E5-4197-B26E-1F259DA1E34F
P2860
Artificial surfactant therapy in hyaline-membrane disease.
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年学术文章
@wuu
1980年学术文章
@zh-cn
1980年学术文章
@zh-hans
1980年学术文章
@zh-my
1980年学术文章
@zh-sg
1980年學術文章
@yue
1980年學術文章
@zh
1980年學術文章
@zh-hant
name
Artificial surfactant therapy in hyaline-membrane disease.
@en
Artificial surfactant therapy in hyaline-membrane disease.
@nl
type
label
Artificial surfactant therapy in hyaline-membrane disease.
@en
Artificial surfactant therapy in hyaline-membrane disease.
@nl
prefLabel
Artificial surfactant therapy in hyaline-membrane disease.
@en
Artificial surfactant therapy in hyaline-membrane disease.
@nl
P2093
P1433
P1476
Artificial surfactant therapy in hyaline-membrane disease.
@en
P2093
P356
10.1016/S0140-6736(80)90489-4
P407
P577
1980-01-01T00:00:00Z